ClinicalTrials.gg
RecruitingNCT06364150MAGICcell6Updated Dec 3, 2024

Therapeutic Use of Angiopoietin-Primed Autologous Peripheral Blood Stem Cell in Myocardial Infarction

A Phase 3 interventional study of Autologous Peripheral Blood Stem Cell injection in Acute Myocardial Infarction, sponsored by Seoul National Hospital. Recruiting at 1 site in Korea, Republic of. Open to participants aged 19 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-12-03.

Sponsored by Seoul National Hospital · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by May 2025, 1 year 6 months ago, but the record still lists the study as recruiting.
  • Started Jul 2024; still recruiting 2 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
19 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 99 studies in Myocardial Infarction with a site in Korea, Republic of — 21 open to participants now, 26 under way, 5 of them phase 3. Myocardial Infarction · Korea, Republic of.

Planned enrollment
69th of 73
30 · median 820
Started
2024
with 3 others
Phase 3
22 of 99
2 open now
Primary completion
2025-05
later than 3 of 25 live
Registered
90th of 99
by date

Among the 99 studies in Myocardial Infarction with a site in Korea, Republic of, this one is the 69th largest by planned enrollment of the 73 interventional ones that give a count, is one of 4 that started in 2024, is one of 22 in phase 3, reaches primary completion later than 3 of the 25 other live ones, and was the 90th registered.

Myocardial Infarction

2,273 studies on the registry are indexed under Myocardial Infarction; 373 are open to participants now.

Browse Myocardial Infarction studies →

Open to participants now

21 of the 99 studies in Myocardial Infarction with a site in Korea, Republic of are open now. Recruiting first, the newest first:

15 more — sign in →

All 21 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 256 Myocardial Infarction studies recruiting now, 173 (68%) set no upper age limit and 25 (10%) stop at 75 or younger; 17 take children under 18; 27 take healthy volunteers.

This study: 19 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 99 studies in Myocardial Infarction with a site in Korea, Republic of, or all of them as a file.
02

Study summary

This study will evaluate the efficacy and safety of "Therapeutic Use of Autologous-Primed Autologous Peripheral Blood Stem Cell Treatment for Myocardial Regeneration in Acute Myocardial Infarction".

Read the detailed description

Patients diagnosed with acute myocardial infarction will receive percutaneous coronary intervention to the culprit coronary artery according to standard procedures. For peripheral blood stem cell mobilization, Granulocyte colony-stimulating factor (G-CSF) and erythropoietin (EPO) will be injected for a total of 4 days, followed by collection of mobilized peripheral blood stem cell (mobPBSC) via apheresis. In ex-vivo setting, mobPBSC will be primed with angiopoietin 1 (Ang1) for 1 hour. A total of 2 X109 Ang1 primed mobPBSC will be injected to the culprit artery.

03

Conditions studied

  • Acute Myocardial Infarction

Keywords

  • Peripheral Blood Stem Cell Treatment
  • Acute Myocardial Infarction
04

Who can participate

Ages eligible
19 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. Male and female aged ≥19 years and ≤ 80 years
    1. A clinical diagnosis of acute myocardial infarction within 4 weeks from randomization
    1. Successful percutaneous coronary intervention to the target lesion (TIMI flow grade 3 and residual stenosis \<30% at the target lesion) with a drug-eluting stent and/or drug-eluting balloon
    1. Agreement to give written .

Exclusion criteria

Exclusion Criteria:

  1. Patients with uncontrolled heart failure (Killip class ≥ grade 2, or \<20%)
  2. Patients with uncontrolled chest pain due to ischemia
  3. Patients with uncontrolled arrythmia
  4. Active , or incompletely treated malignancy
  5. Active infectious disease
  6. Uncontrolled hematologic disease, including coagulopathy or bleeding diathesis
  7. Presence of non-cardiac comorbidity with ≤1 year from randomization
  8. Females with or breast-feeding
  9. Refusal to give written
  10. Other conditions that may result in protocol non-compliance by the committees
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Cell treatment arm

    Patients who receive Angiopoietin-Primed Autologous Peripheral Blood Stem Cell in Myocardial Infarction

    Biological: Autologous Peripheral Blood Stem Cell injection

Interventions

  • BiologicalAutologous Peripheral Blood Stem Cell injection

    For peripheral blood stem cell mobilization, G-CSF and EPO will be injected for a total of 4 days, followed by collection of mobPBSC via apheresis. In ex-vivo setting, mobPBSC will be primed with Ang1 for 1 hour. A total of 2 X109 Ang1 primed mobPBSC will be injected to the culprit artery.

06

What researchers measure

Primary outcomes

  1. Left ventricular systolic function

    Left ventricular ejection fraction measured by echocardiography (measured in percent)

    Time frame: 12 months after treatment

Secondary outcomes

  1. Regional wall motion score index

    Regional wall motion score index measured by echocardiography. The score is scaled from 1.0 to 4.0. Using a standard transthoracic echocardiography sequence, each one of the 16 myocardial segments are assigned a score from 1 to 4. The scores for 16 segments are scaled as normokinesia (1 point) or hypokinesia (2 points) or akinesia (3 points) or dyskinesia (4 points). A score of 1.0 is considered normokinetic, and a score of 3.0 correlated as akinetic.

    Time frame: 12 months after treatment

  2. B-natriuretic peptide level

    Laboratory test which is measured in picograms per milliliter (pg/ml).

    Time frame: 12 months after treatment

  3. 6-minute walk test

    6-minute walk test is measured in meters.

    Time frame: 12 months after treatment

  4. All-cause death

    Rate of patients with a mortality event due to any cause

    Time frame: 12 months after treatment

  5. Target lesion Revascularization

    Rate of patients who received additional revascularization for the target lesion (the coronary lesion that was treated at the index procedure)

    Time frame: 12 months after treatment

  6. Readmssion

    Rate of patients who were readmitted due to any cause

    Time frame: 12 months after treatment

  7. Cardiovascular death

    Rate of patients with a mortality event due to cardiovascular cause

    Time frame: 12 months after treatment

  8. non-Target lesion Revascularization

    Rate of patients who received additional revascularization for a non-target lesion (the coronary lesion that was NOT treated at the index procedure)

    Time frame: 12 months after treatment

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Any request for data sharing should be sent as an inquiry to the principle investigator.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for May 2025, 9 months after the start.

Of 34 non-industry phase 3 interventional studies under Myocardial Infarction, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 73. This study's planned 9 months is below that.

Counting every sponsor, half of 58 studies reached it within 44 months; a quarter within 30 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2024
First posted
Apr 15, 2024
StartActual
Jul 15, 2024
Primary completionEst.
May 1, 2025
CompletionEst.
Aug 1, 2026
Last update
Dec 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06364150
Lead sponsor
Seoul National Hospital
Responsible party
Hyun-Jai Cho (Professor, Seoul National University Hospital) — Principal investigator
First posted
Apr 15, 2024
Start date
Jul 15, 2024
Primary completion
May 1, 2025 (estimated)
Completion
Aug 1, 2026 (estimated)
Last update
Dec 3, 2024

Study contacts

Jeehoon Kang, MD
Contact
medikang@gmail.com
+821024162406
Hyun Jai Cho, MD
principal investigator · Seoul National University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion